Clinical Pharmacology

Polypharmacy in the Caribbean — The Clinical Challenge of Multiple Medications in Older Patients

The Caribbean's high burden of non-communicable disease produces a predictable polypharmacy problem in older patients. The clinical tools for screening exist. They are not consistently applied.

ElesRx  |  PIPPS Smart Apps  |  J.C. Epiphany Limited, Jamaica

Polypharmacy — conventionally defined as the concurrent use of five or more medications — is among the most significant and underaddressed patient safety challenges in Caribbean clinical practice. It is not a new problem, but the conditions that drive it are worsening. As the Caribbean population ages and the prevalence of non-communicable diseases continues to rise, the proportion of patients managing complex multi-drug regimens increases correspondingly.

The clinical consequences of unmanaged polypharmacy are well-documented: increased risk of adverse drug reactions, drug-drug interactions, prescribing cascades, medication non-adherence, falls, cognitive impairment, hospitalisation, and mortality. In older patients, these risks are amplified by age-related changes in pharmacokinetics and pharmacodynamics that alter how drugs behave at every stage from absorption to elimination.

"Polypharmacy is not simply a matter of too many drugs. It is a matter of drugs whose combined effect has not been systematically evaluated in the context of the individual patient's age, renal function, hepatic function, cognitive status, and the full interaction surface of their regimen. That evaluation does not happen automatically. It requires tools and deliberate clinical attention."

Why the Caribbean Context Amplifies the Risk

Several features of Caribbean healthcare delivery and population health create conditions in which polypharmacy risk is particularly high.

High NCD Co-morbidity

Hypertension, type 2 diabetes, dyslipidaemia, and heart failure frequently co-occur in Caribbean patients. Each condition typically requires multiple agents to achieve guideline targets. A patient with all four conditions may be on eight to twelve medications before any consideration of symptom management or comorbidity treatment.

Multi-Prescriber Fragmentation

Patients often attend both public and private healthcare settings, see multiple specialists, and self-medicate with OTC products. No single prescriber routinely has sight of the complete medication list without active reconciliation — which is inconsistently performed across the region.

Age-Related Pharmacokinetic Changes

Renal function declines with age, reducing clearance of renally-eliminated drugs. Hepatic metabolism slows. Body composition changes alter drug distribution. Older patients experience drug effects — and adverse effects — at doses that would be unremarkable in younger adults.

Limited Medication Review Infrastructure

Formal structured medication reviews, routine in the UK NHS and increasingly standard in North American practice, are not consistently embedded in Caribbean primary care. The clinical pharmacist role in community and primary care settings remains underdeveloped across much of the region.

The Prescribing Cascade — Polypharmacy's Hidden Driver

A prescribing cascade occurs when the adverse effect of one drug is interpreted as a new medical condition and treated with an additional drug, whose own adverse effects may then generate further prescriptions. Each step in the cascade increases the drug burden and the interaction surface without addressing the underlying cause — the original offending medication.

Common cascade patterns in Caribbean practice include: an ACE inhibitor causing a dry cough, treated with an antihistamine or antitussive rather than switching to an ARB; a thiazide diuretic causing gout, treated with allopurinol rather than reviewing the diuretic; a calcium channel blocker causing ankle oedema, treated with a loop diuretic rather than switching agent. ElesRx currently screens for forty-five prescribing cascades across six clinical themes.

Clinical Screening Tools Available in ElesRx

Tool What It Screens Relevance to Caribbean Practice
ElderWatch — Beers Criteria Flags drugs from the AGS Beers Criteria potentially inappropriate in patients aged 65 and over. 132 drugs currently covered. Directly applicable. Several Beers Criteria drugs remain in common use in Caribbean geriatric practice — benzodiazepines, first-generation antihistamines, certain antihypertensives.
Anticholinergic Burden Scoring Calculates cumulative anticholinergic burden across the full medication list using the ACB scale. High anticholinergic burden is associated with cognitive impairment, falls, urinary retention, and constipation — all prevalent in older Caribbean patients. Multiple drugs with moderate anticholinergic activity combine to produce clinically significant cumulative burden.
Prescribing Cascade Detection Identifies patterns where a drug may have been added to treat the adverse effect of another drug. 45 cascades across 6 clinical themes. Particularly relevant in multi-prescriber environments where the cascade origin may not be visible to the treating clinician.
Therapeutic Duplicate Detection Identifies two drugs from the same class prescribed concurrently without documented clinical justification. Common in patients who transition between prescribers or healthcare settings — a drug may be continued from one setting while a new prescription for the same class is issued in another.
Drug-Drug Interaction Checking Bidirectional interaction screening across the full medication list with severity classification and mechanism. Interaction risk increases non-linearly with the number of drugs in a regimen. A ten-drug regimen has a vastly larger interaction surface than a five-drug regimen.

A Practical Approach to Polypharmacy Review in Caribbean Practice

Clinical Review Framework

Polypharmacy in older Caribbean patients is not a problem that resolves without deliberate clinical attention. The tools to screen for its consequences — inappropriate prescribing, high anticholinergic burden, prescribing cascades, dangerous interactions — exist and are available within ElesRx. Applying them systematically at each clinical review is the practical intervention that reduces risk at the individual patient level.

This article is intended for qualified prescribers, pharmacists, and licensed healthcare professionals. It is a clinical overview, not a prescribing guideline. Decisions regarding medication review, deprescribing, or regimen modification should always be made in the context of the full clinical picture, patient preferences, and current evidence-based guidelines. ElesRx is a decision support tool — clinical judgment remains with the prescribing clinician.

Screen for Polypharmacy Risk in ElesRx

ElderWatch, anticholinergic burden scoring, cascade detection, and interaction checking — built for Caribbean clinical practice.

Access ElesRx
JD
Juliet Duncan, BPharm

Juliet is a pharmacist and the developer of ElesRx, a clinical decision support tool for Caribbean clinicians. ElesRx is part of the PIPPS Smart Apps suite, developed by J.C. Epiphany Limited, Jamaica. Est. 1999.

← Back to all articles